Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

ACWY Vax antibody persistence shorter than expected

The manufacturer of ACWY Vax® has written to healthcare professionals advising that antibody titres wane after between one and two years, not at least three years as stated in the product literature.

Recent studies for a new meningococcal vaccine used the ACWY Vax as a comparator. Analysis of two of these studies identified reduced serum bacterial antibody titres one year post-vaccination when using human compliment in the assay.

Individuals who remain at high risk of exposure to Neisseria meningitides may require re-vaccination and earlier than is currently recommended in the current product literature.

It has already been announced that ACWY Vax is being discontinued this year.

Action: Clinicians who use and administer meningococcal vaccines should be aware of this new information and the need to consider earlier re-vaccination if necessary for previous recipients of ACWY Vax.

Share 'ACWY Vax antibody persistence shorter than expected' on Email Share 'ACWY Vax antibody persistence shorter than expected' on Delicious Share 'ACWY Vax antibody persistence shorter than expected' on Digg Share 'ACWY Vax antibody persistence shorter than expected' on Facebook Share 'ACWY Vax antibody persistence shorter than expected' on Google+ Share 'ACWY Vax antibody persistence shorter than expected' on reddit Share 'ACWY Vax antibody persistence shorter than expected' on StumbleUpon Share 'ACWY Vax antibody persistence shorter than expected' on Twitter

atomic-wealth

No Comments to “ACWY Vax antibody persistence shorter than expected”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,316 spam comments.

atomic-wealth
fond-illness
summer